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Activation of mitogen/extracellular-signal-regulated kinase kinase 5/extracellular signal-regulated kinase-5 (MEK5/ERK5) growth
signalling is coupled to increased cell proliferation in prostate cancer (PCa). Dysregulation of the DNA replication licensing pathway, a
critical step in growth control downstream of transduction signalling pathways, is associated with development of PCa. In this study
we have investigated linkages between the MEK5/ERK5 pathway and DNA replication licensing during prostate carcinogenesis. The
effects of increased MEK5/ERK5 signalling on the expression of replication licensing factors Mcm2 and geminin and the proliferation
marker Ki67 were studied in an ecdysone-inducible system expressing a constitutively activated mutant of MEK5 in EcR293 cells and
in stable ERK5 over-expressing PC3 clones. In parallel, expression of these biomarkers in PCa biopsy specimens (n¼58) was studied
and compared to clinicopathological parameters. In both in vitro systems induction of MEK5 expression resulted in increased levels
of phosphorylated ERK5 and Mcm2, geminin and Ki67 proteins. In PCa specimens average Mcm2 expression was greater than Ki67
and geminin expression (median labelling index (LI) 36.7, 18.1, and 3.4% respectively), consistent with their differential expression
according to growth status (Po0.0001). Mcm2, geminin and Ki67 expression were significantly associated with Gleason grade
(P¼0.0002, P¼0.0003, P¼0.004); however there was no link with T or M stage. There was a significant relationship between
increasing ERK5 expression and increasing Mcm2 (P¼0.003) and Ki67 (P¼0.009) expression, with non-significant trends seen with
increasing MEK5 expression. There were significant associations between Gleason grade and the number of cells traversing G1 phase
(Ki67LI-gemininLI;( P¼0.001)), with high ERK5 levels associated with both an increase in replication licensed but non-cycling cells
(Mcm2LI-Ki67LI;( P¼0.01)) and accelerated cell cycle progression (gemininLI/Ki67LI;( P¼ 0.005)), all indicative of a shift towards
increasing proliferative potential. While Mcm2 and Ki67 were both prognostic factors on univariate analysis, only Mcm2 remained an
independent prognostic marker on multivariate analysis. Taken together, our data show that induction of MEK5/ERK5 signalling is
linked to activation of the DNA replication licensing pathway in PCa, and that the strong prognostic value of MCM proteins may
result from their function as relay stations coupling growth regulatory pathways to genome duplication.
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Prostate cancer (PCa) is the commonest cancer affecting men in
the UK, with 30140 new cases per year representing 22% of new
male cancers. The 5-year relative age standardized survival for
patients diagnosed with PCa is 65%, accounting for 9940 deaths
per year and making PCa the second leading cause of cancer death
(Cancer Research UK, 2005). PCa has a broad spectrum of
pathological behaviour. Many patients with PCa will die of other
causes due to the indolent nature of their disease, while others will
progress and die of metastatic disease despite radical therapy.
Treatment selection is based on patient’s age and health status, as
well as prognostic factors such as Gleason grade, TNM stage and
serum prostate specific antigen (PSA). Histological Gleason grade
currently gives the most accurate assessment of growth status of
PCa; however, it is prone to inter- and intra-observer error
(Gleason, 1992). As for many cancers, improved prognostic
markers for clinical application are urgently sought to aid
treatment selection and to identify high-risk patients.
The mitogen/extracellular-signal-regulated kinase kinase 5/
extracellular signal-regulated kinase-5 (MEK5/ERK5) pathway
has been implicated in the regulation of cell proliferation.
Mitogen-activated protein (MAP) kinase kinases (MEKs/MAPKKs)
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srepresent a family of protein kinases upstream of MAP kinases that
play a pivotal role in regulation of cell proliferation and apoptosis.
MEK5 is the most recently identified MAPKK and encodes a 444-
amino-acid protein with an overall 40% homology to other MEK
proteins (English et al, 1995; Zhou et al, 1995). MAPKK specifically
activates ERK5, also known as Big MAP kinase 1, which is almost
twice the size of other MAPKs (Zhou et al, 1995). The activities of
several transcriptional factors have been shown to be regulated by
ERK5, including MEF2, c-Fos and Fra1, Sap-1, c-Myc and NF-kB
(Kato et al, 1997; English et al, 1998; Pearson et al, 2001; Barsyte-
Lovejoy et al, 2002; Terasawa et al, 2003). We have previously
demonstrated that MEK5 overexpression is associated with
metastatic PCa, and that it is able to induce proliferation, motility
and invasion in PCa cells. Moreover increased MEK5 and ERK5
expression correlates with presence of bony metastases and less
favourable disease-specific survival (Mehta et al, 2003). These
independent markers of prognosis are currently being tested as
stratification tools for identification of PCa with an aggressive
phenotype.
The initiation of DNA replication is a critical step in growth
control that lies downstream of the RAS-RAF-MEK-MAP kinase
signal transduction pathway. It is dependent on the assembly onto
chromatin of pre-replicative complexes (pre-RCs) containing
Orc1–6, Cdc6, Cdt1 and minichromosome maintenance (Mcm)
2–7 proteins during G1 phase, thereby rendering replication
origins ‘licensed’ for one round of DNA synthesis during S phase.
At the G1-S transition pre-RCs are activated by cyclin-dependent
kinases (CDKs) and Cdc7/ASK kinase, resulting in recruitment of
additional initiation factors and DNA polymerase a-primase to
the origin, unwinding of the DNA helix, and initiation of DNA
synthesis (Machida et al, 2005). DNA replication initiation is
tightly coupled to removal of the license. This step is critical as
origins must fire once-and-only-once in each cell cycle to ensure
genomic stability. To avoid re-licensing, mammalian cells have
adopted a number of mechanisms. These include inactivation of
replication licensing factors (RLFs) during S, G2 and M phase (a
process controlled by CDK activity), regulated proteolysis, and
changes in gene expression (Machida et al, 2005). Arguably the
most important mechanism of preventing re-replication is the
expression of a repressor of origin licensing, known as geminin,
which acts by competitively binding Cdt1, thereby blocking MCM
loading and hence pre-RC re-assembly onto chromatin (Blow and
Dutta, 2005). Geminin expression is tightly restricted to S, G2 and
M phase of the cell cycle, in keeping with its function of preventing
re-replication (Wharton et al, 2004). The constituents of the pre-
RC can be regarded as relay stations coupling growth regulatory
pathways with DNA replication (Williams and Stoeber, 1999). We
and others have demonstrated in a range of different tumour types
that dysregulation of the MCM proteins is an early event in
tumourigenesis and have exploited these biomarkers in primary
diagnosis, tumour surveillance and prognosis (Williams et al,
1998, 2004; Stoeber et al, 1999, 2002; Wharton et al, 2001, 2004;
Davies et al, 2002; Going et al, 2002; Gonzalez et al, 2003; Kruger
et al, 2003; Padmanabhan et al, 2004; Dudderidge et al, 2005;
Korkolopoulou et al, 2005; Shetty et al, 2005). These studies have
established that the superior sensitivity of MCM proteins over the
standard proliferation marker Ki67 resides in the fact that these
biomarkers identify not only cycling cells but also non-cycling
cells with proliferative potential (Stoeber et al, 2001). Moreover, we
have shown that multiparameter analysis of tumour cell popula-
tions using Mcm2–7, geminin and Ki67 biomarkers allows a
detailed analysis of cell cycle kinetics in biopsy material (Wharton
et al, 2004; Obermann et al, 2005).
Here we have investigated the regulation of growth control in
PCa by investigating linkages between MEK5/ERK5 growth
signalling and the downstream DNA replication (or origin)
licensing pathway (RLP). The MAPK-NFkB pathway is a potent
regulator of cell proliferation through transcriptional control of
cyclin D1 (Guttridge et al, 1999; Hinz et al, 1999), and several of
the genes encoding RLFs appear to be E2F regulated and their
promoter activities growth-dependant (Blow and Hodgson, 2002).
First, we used an ecdysone-inducible in vitro system expressing a
constitutively activated mutant of MEK5 in EcR293 cells in
addition to stable ERK5 overexpressing PC3 clones to determine
the effects of increased MEK5/ERK5 signalling on the RLP in vitro.
Second, we performed protein expression profiling for MEK5,
ERK5, Mcm2, geminin and Ki67 on a series of PCa specimens to
investigate the effects of MEK5/ERK5 signalling on origin licensing
and cell cycle kinetics in vivo.
MATERIALS AND METHODS
Antibodies
Mouse anti-human Mcm2 monoclonal antibody (clone 46) was
obtained from BD Transduction Laboratories (Lexington, KY,
USA). Mouse anti-human Ki67 monoclonal antibody (clone MIB-
1) was obtained from DAKO (Glostrup, Denmark). Affinity-
purified rabbit polyclonal antibody against full-length hsgeminin
protein was generated as described (Wharton et al, 2004). Anti-
MEK5 polyclonal antibody was obtained from Stressgen Bio-
technologies (San Diego, CA, USA), anti-ERK5 polyclonal and
anti-HA monoclonal antibody from Santa Cruz Biotechnology (Santa
Cruz, CA, USA), and anti-a-tubulin monoclonal antibody from
Sigma-Aldrich (Gillingham, Dorset, UK). Anti-ERK5 polyclonal
antibody for use in immunohistochemistry was a kind gift from
Professor P Cohen (University of Dundee, UK) (Mody et al, 2001).
Plasmid construction and generation of stable clones
An ecdysone-inducible system expressing a constitutively activated
mutant of MEK5 in EcR293 cells was used to determine the effects
of increased MEK5/ERK5 signalling on the DNA RLP. Stable clone
EcRD No. 16 has previously been shown to have negligible
background and high Ponasterone A (PonA)-induced MEK5D
expression (Mehta et al, 2003). Following induction of MEK5
expression with 5mM PonA for 24h, whole cell lysates were
subjected to SDS–PAGE and immunoblot analysis. In addition to
the ecdysone-inducible system, an ERK5 over-expressing PCa
stable clone was generated. ERK5 was amplified from a full-length
clone (Bouras et al, 2001) using oligonucleotides MP405
(GGATCCGCCGAGCCTCTGAAGGAGGAAG) and MP1310
(GCGGATCCTCAGGGGTCCTGGAGGTCAGG) with GC Rich PCR
System (Roche, Lewes, East Sussex, UK). The resulting fragment
was cloned into pCR2.1 (Invitrogen, Paisley, UK), sequenced, then
subcloned into EGFP-C1 (Clontech, Palo Alto, CA, USA) to form
EGFP-C1 ERK5. PC3 cells overexpressing ERK5 were generated by
transfection with EGFP-C1 ERK5 using Superfect
s Transfection
Reagent (Qiagen, Crawley, UK) according to the manufacturer’s
recommendations. Following selection with geneticin (G418,
1mgml
 1; Sigma-Aldrich, Gillingham, Dorset, UK), colonies were
left to form for 2–3 weeks. Control stable cell lines were similarly
established with the vector (EGFP-C1) alone. Individual colonies
were subcultured and screened for ERK5 expression by immuno-
blotting. Presence and subcellular localisation of ERK5 were also
determined by fluorescent microscopy.
Immunoblotting
Cells were lysed directly on plates with 6  SDS sample buffer
containing 10% b-mercaptoethanol. Samples were denatured and
proteins separated by SDS–PAGE, followed by transfer to
nitrocellulose. Antibodies were used at the following dilutions:
anti-HA, 1:500; anti-ERK5, 1:1000; Mcm2, 1:3000; Ki67, 1:2500;
geminin, 1:1000; and anti-a tubulin, 1:2000. Horseradish
peroxidase-conjugated secondary antibodies were applied
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s(1:500) and detected using an enhanced chemiluminescence
detection kit (ECL, Amersham, Bucks, UK).
Immunofluorescence and confocal microscopy
PC3 cells stably overexpressing ERK5 (PC3-ERK5) and PC3 cells
overexpressing the empty vector alone (PC3-EmptyVector) were
seeded onto sterile coverslips in 6-well plates (Corning Incorpo-
rated, Corning Life Sciences, One The Valley Centre, Gordon Road,
High Wycombe, Bucks, UK) at densities of 3 10
4 cells/well. After
24h, cells were washed and incubated in Basal Media overnight.
Cells were stimulated with EGF for 30min and immediately fixed
with 100% methanol at  201C for 30min. To prevent non-specific
staining, fixed cells were first blocked in 10% natural rabbit serum
(DakoCytomation) for 30min at RT. Blocking solution was
subsequently removed and primary antibodies were added at the
following dilutions: anti-ERK5, 1:100; anti-Mcm2, 1:200. Cover-
slips were incubated overnight in a humidified atmosphere at 41C.
Cells were washed ( 3) and incubated with rabbit anti-goat
secondary antibody (1:250, DakoCytomation) and rabbit anti-
mouse secondary antibody (1:250, DakoCytomation) for 1h at RT
in the dark. Vectashield with 4,6-diamidino-2-phenylindole
(DAPI), for nuclear counterstain, was used to mount slides.
Images of fixed cells were acquired with a Leica TCS SP2 UV laser-
scanning microscope using a  63 oil immersion lens (1.32 NA
DIC). A series of 1mm vertical optical sections through the entire
thickness of the cells was used to produce a Z-series and all images
were analysed using LCS 2.00.585 software. Controls, lacking
primary antibody, failed to show any staining.
Human prostate tissue samples
Ethical approval for tissue studies was obtained from the research
ethics committee of the Freeman Hospital, Newcastle-upon-Tyne,
UK. Consent for the use of surplus tissue obtained at the time of
diagnosis was gained from patients undergoing transurethral
resection of the prostate for bladder outflow obstruction.
Diagnosis of PCa was made by histopathological examination.
This cohort of patients was managed by surveillance and
subsequent androgen suppression. Formalin-fixed and paraffin
wax-embedded tissue blocks containing greater than 75% tumour
involvement were selected for analysis, and tissue sections were cut
at 4mm thickness. The cohort included 58 PCa patients with a
median age of 75 years (range 55–88). Included in the series were
Gleason grades from 6 to 10 (Gleason 6: n¼9 (16%), Gleason 7:
n¼7 (12%), Gleason 8: n¼25 (43%), Gleason 9: n¼12 (21%),
Gleason 10: n¼5 (9%)) and a range of clinical tumour (T) stages
as determined by rectal examination (T1: n¼13 (22%), T2: n¼15
(26%), T3: n¼17 (29%), T4: n¼5 (9%)). Staging data were
missing in eight (14%) patients. Nearly all patients (56/58) had a
radionucleide bone scan at the time of diagnosis. The group
included 28 (48%) patients with and 28 (48%) patients without
evidence of bony metastasis. It should be noted that the patients in
this cohort were recruited in the pre-PSA era, and thus PSA data
were not available. At the time of our study, 45 (78%) patients had
died and eight (14%) were alive. Survival times for five patients
were unknown, and these patients were excluded from the survival
analysis. In the survivors the follow-up ranged from 2 to 142
months, with a mean of 71.6 months (s.d.¼55.4).
Immunohistochemical analysis
Mcm2, geminin and Ki67 Immunohistochemical staining for
Mcm2, geminin and Ki67 was performed as described (Dudderidge
et al, 2005). Incubation without primary antibody was used as a
negative control, and colonic epithelial sections were used as
positive controls. To determine the labelling index (LI) in each
tumour, slides were evaluated at low power ( 100) to identify
regions of tumour with the most intense degree of staining. From
selected areas, three to five fields at  400 magnification were
captured with a charged coupled device camera and analySIS
software (SIS, Mu ¨nster, Germany). Images were subsequently
printed for analysis. Quantitative analysis was undertaken with the
observer unaware of the clinicopathologic variables. Cells were
identified as positive if there was any nuclear staining present, and
any stromal or inflammatory cells on the field were excluded. A
mean of 893 nuclei were counted for each case. The LI was
calculated by dividing the number of positive cells by the total
number of cells counted. Reassessment of 10 randomly selected
cases by an independent observer showed high inter-observer
agreement.
MEK5 and ERK5 Immunohistochemical staining for MEK5 was
performed as described (Mehta et al, 2003). For ERK5 protein
expression analysis, paraffin wax-embedded serial sections (4mm)
were incubated overnight at 41C with anti-ERK5 goat polyclonal
antibody at 1:200 dilution and immunohistochemical analysis was
performed as described (Gnanapragasam et al, 2003). The staining
was developed with diaminobenzidine tetrahydrochloride (DAB;
Sigma, UK), with haematoxylin used as counterstain. Heart muscle
was used as a positive control; no primary antibody as a negative
control. Levels of MEK5 and ERK5 immunoreactivity were graded
as absent (0), weak (1), moderate (2), or strong (3) by two
independent observers with high inter-observer agreement.
Statistical analysis
The association between all-cause mortality and marker expression
was assessed using Kaplan–Meier curves and the log-rank test,
using the ‘minimum P-value approach’ with adjusted P-values
and a significance level of 0.05 (Faraggi and Simon, 1996). A
multivariate Cox proportional hazards model was fitted using a
backwards stepwise procedure to investigate trends between
marker expression and the standard prognostic variables Gleason
grade, T stage, presence of bony metastases, and survival.
Statistical significance of trends between markers and standard
prognostic variables was assessed using the Mann–Whitney U and
Jonckheere–Terpstra tests. In this secondary analysis, P-values
of less than 0.01 were regarded as statistically significant. The
Wilcoxon signed-rank test was used to compare overall labelling
indices of Mcm2, geminin and Ki67. Analysis was performed using
SPSS 12.0 for Windows (SPSS Inc., Chicago, IL, USA) and R
version 2.0.
RESULTS
Increased MEK5/ERK5 signalling enhances Mcm2, geminin
and Ki67 expression
To investigate potential linkages between the MEK5/ERK5 signal-
ling pathway and the downstream DNA replication (or origin)
licensing pathway (RLP), we first used an ecdysone-inducible
system to express a constitutively activated mutant of MEK5
(MEK5D) in EcR293 cells (Mehta et al, 2003). Clone EcRD No. 16
showed negligible background MEK5 expression (Mehta et al,
2003). Treatment of cells for 24h with Ponasterone A (PonA)
resulted in a two-fold increase in the percentage of cells in S phase
(Figure 1A). MEK5D expression was potently induced and was
associated with a shift in the size of the ERK5 band, in keeping
with ERK5 phosphorylation (Figure 1B). ERK5 is the only known
substrate of MEK5 and, like other MAPK family members, it is
activated by phosphorylation (Abe et al, 1996). Induction of the
MEK5/ERK5 signalling pathway was coupled to a marked increase
in the expression of Mcm2 and geminin, and also to upregulation
of the standard proliferation marker Ki67 (Figure 1C). Next we
used PC3 cells stably overexpressing ERK5 (PC3-ERK5 cells) to
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a background level of endogenous ERK5 (Figure 2A). The ERK5
overexpressing clone produced much higher levels of EGFP-fused
ERK5 and WST-1 cell proliferation assays showed a B3-fold
increase in proliferation compared to empty vector and parental
controls. In keeping with the observations in the inducible system,
the ERK5 overexpressing PC3 line expressed higher levels of
Mcm2, geminin and Ki67 protein (Figure 2B–D). Indirect
immunofluorescence studies also showed increased Mcm2 expres-
sion in ERK5 overexpressing cells (Figure 2E–F), confirming the
immunoblot data, which give a population mean, at the level of
individual cells. Taken together, these data demonstrate linkage of
the MEK5/ERK5 signalling pathway with the replication licensing
system in human prostatic cancer cells.
Patient characteristics
To investigate coupling of MEK5/ERK5 signalling to the RLP in
vivo and cell cycle kinetics of PCa, we analysed biopsy material
from a cohort of PCa patients diagnosed after transurethral
resection of the prostate (for clinical characteristics of the study
cohort see Materials and Methods). Clinicopathological and
immunohistochemical data were available for the entire cohort;
however, five patients have been excluded from the survival
analysis because survival times were unknown.
DNA replication licensing in normal prostate and prostate
cancer
The pattern of RLF expression was first assessed in morphologi-
cally normal prostate tissue present in the biopsy material.
Expression of Mcm2, geminin and Ki67 was extremely low
(o2%), consistent with our previous finding that loss of
proliferative capacity which accompanies differentiation is coupled
to repression of origin licensing through down-regulation of the
Mcm2–7 RLFs (Stoeber et al, 2001; Eward et al, 2004). In PCa, on
the contrary, Mcm2 and geminin protein levels were high,
indicative of cell cycle re-entry (Kingsbury et al, 2005).
Relationship between Mcm2, geminin and Ki67 protein
expression and clinicopathological characteristics
Distribution of LIs, median and inter-quartile ranges for each
marker are shown in Table 1 and Figure 3, and immunohisto-
chemical staining of representative cases of Gleason grade 6, 8 and
10PCa is illustrated in Figure 4. Mcm2 protein expression in these
tumours was significantly greater than Ki67 expression, which was
itself significantly higher than geminin expression [median: Mcm2,
36.7%; Ki67, 18.1%; geminin, 3.4% (Po0.0001, Wilcoxon signed-
rank test)]. Furthermore Mcm2 expression was distributed over a
far broader range than Ki67 or geminin (Mcm2: 2.7–100%; Ki67:
2.2–77.8%; geminin: 0.3–37.2%). The high percentage of Mcm2-
expressing cells compared to Ki67 can be explained by the
presence of replication licensed but non-cycling cells in addition to
proliferating cells (Stoeber et al, 2001; Blow and Hodgson, 2002).
The low growth fraction identified by geminin compared with Ki67
is due to geminin expression being restricted to S, G2 and M phase
(Eward et al, 2004; Wharton et al, 2004). There was a clear
association of increasing Mcm2, geminin and Ki67 LIs with
increasing Gleason grade (Mcm2, P¼0.0002; geminin, P¼0.0003;
Ki67, P¼0.004; Table 1 and Figure 4). Figure 5 shows more clearly
the mean and distribution of Mcm2 LIs for each grade. Although
there is an increase in mean Mcm2LI with increasing grade, notably
a high Mcm2LI does not preclude the possibility of low Gleason
grade. A statistically significant link between increasing Gleason
grade and Ki67LI-gemininLI (P¼0.001) was also observed,
indicating an increase in the population of cells entering G1 phase
in more poorly differentiated tumours. There was no significant
association between T stage and bony metastases with Mcm2,
geminin or Ki67 expression.
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Figure 1 (A) FACS analysis. EcRD No. 16 cells were serum-starved for 16h and uninduced/induced for MEK5 expression by PonA for 0, 8, 16 and 24h.
Cells were stained by propidium iodide before analysis by flow cytometry. Duplicate samples were analysed for each of the time points. Bars represent mean
values of the percentage of cells in G1, S or G2/M phase of the cell cycle. Experiments were repeated in triplicate. Left panel, uninduced; right panel, induced
with PonA. MEK5 expression resulted in a two-fold increase in the percentage of cells in S phase. (B) Authenticity of clone. Clone EcRD No. 16 was either
uninduced/induced with 5mM PonA for 24h before screening whole cell lysates by immunoblotting with antibodies against HA tag (top), ERK5/
phosphorylated ERK5 (middle) and a-tubulin (bottom). (C) Increased MEK5/ERK5 signalling was linked to increased Mcm2, geminin and Ki67 protein levels.
EcRD No. 16 cells were either uninduced/induced with 5mM PonA for 24h before screening whole cell lysates by immunoblotting with antibodies against
Mcm2, geminin and Ki67.
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Ki67 protein levels
We sought to identify the relationship between the MEK5/ERK5
growth signalling pathway and the RLFs Mcm2 and geminin, as
well as the standard proliferation marker Ki67. Table 1 sum-
marizes the links between these markers according to the degree of
protein expression. The trends of increasing Mcm2, geminin and
Ki67 expression with increased MEK5 expression are less marked.
These weaker associations may reflect the fact that MEK5 lies
upstream of ERK5 in the growth signalling pathway. We have
previously stated that the RLP lies at a convergence point in
growth signalling (Williams and Stoeber, 1999; Stoeber et al, 2001)
and these data strongly support this hypothesis.
Linkages between DNA replication licensing, MEK5/ERK5
signalling, and cell cycle kinetics in prostate cancer
We have previously shown that RLF expression analysis can
provide novel insights into the cell cycle kinetics of tumours. The
Mcm2LI minus Ki67LI (Mcm2 Ki67) identifies the replication
licensed but non-proliferating population of tumour cells, whereas
the Ki67LI minus gemininLI (Ki67 geminin) represents the
proportion of tumour cells in G1 phase (Stoeber et al, 2001,
2002; Dudderidge et al, 2005; Obermann et al, 2005). Geminin
identifies the proportion of tumour cells traversing through S-G2-
M phase, and therefore the gemininLI to Ki67LI ratio (geminin/
Ki67) provides a measure of the relative length of G1 in dynamic
cell populations, with higher geminin/Ki67 ratios corresponding to
a shortening in the length of G1 phase (Eward et al, 2004; Wharton
et al, 2004; Shetty et al, 2005). In this study, a statistically
significant link between increasing Gleason grade and Ki67-
geminin (P¼0.001; Table 1) was observed, indicating an increase
in the proportion of cells entering G1. Moreover, there was a
significant relationship between increasing ERK5 protein expres-
sion and increasing Mcm2 (P¼0.003) and Ki67 (P¼0.009)
expression (Table 1), recapitulating the data generated in the in
vitro tissue culture model system (Figure 1). Furthermore, there
was a statistically significant link between high ERK5 expression
and increased Mcm2-Ki67 (P¼0.01; Table 1), signifying an
increase in the proportion of non-cycling tumour cells that are
licensed for replication. We also observed a significant trend of
increasing ERK5 expression with increasing geminin/Ki67 ratio,
indicative of a relative shortening in the length of G1 phase and
thus accelerated cell cycle progression (P¼0.005; Table 1 and
Figure 6).
Mcm2, geminin and Ki67 expression and disease-free
survival: univariate and multivariate analyses
The association between all-cause mortality and biomarker
expression was assessed using Kaplan–Meier curves and the log-
rank test, using the ‘minimum P-value approach’ with adjusted
P-values and a significance level of 0.05 (Faraggi and Simon, 1996).
Survival analyses were performed for Mcm2, geminin and Ki67. A
statistically significant association was found between lower Mcm2
protein expression and increased survival time (P¼0.03;
Figure 7A), and between lower Ki67 expression and increased
survival time (P¼0.002; Figure 7B). After adjustment of the
P-value (Faraggi and Simon, 1996), the trend between lower
geminin expression and increased survival time was not statisti-
cally significant (P¼0.22; Figure 7C). The optimal cut points used
were 44% for Mcm2, 25% for Ki67 and 9% for geminin. A Cox
proportional hazards model was fitted to investigate trends
between biomarker expression, the standard prognostic variables
of Gleason grade, stage and survival. Increased expression of
Mcm2 (P¼0.005), geminin (P¼0.04) and Ki67 (P¼0.04) and the
replication licensed but non-cycling cell population (Mcm2-Ki67;
P¼0.01) were all associated with significantly reduced survival
time. However, only the strongest predictor of survival, Mcm2, was
retained in the final model, as after adjustment for Mcm2
expression neither geminin, Ki67, Mcm2-Ki67, Ki67-geminin,
geminin/Ki67 nor any of the other prognostic variables were
significantly associated with survival time (hazard ratio for
Mcm2¼4.22; 95% CI (1.56, 11.45); P¼0.005). Figure 7D shows
the relationship between Mcm2 protein expression and survival.
No significant relationships between Gleason grade and survival
or stage and survival were identified. The presence of bony
metastases was weakly associated with a reduction in survival time
(hazard ratio 0.52; 95% CI (0.27, 1.00); P¼0.05).
DISCUSSION
Initiation of chromosomal replication is a critical step in growth
control and thus important in tumourigenesis. It lies at the point of
convergence of all oncogenic and transduction signalling pathways
that trigger proliferation, making it a potentially attractive target
for both diagnostic and therapeutic interventions (Williams and
Stoeber, 1999). RLFs, which form the core of the initiation
machinery, act as relay stations coupling growth regulatory and
DNA damage response pathways to chromosomal replication. We
and others have demonstrated that dysregulation of the replication
Endogenous ERK5
EGFP-ERK5
-Tubulin
-Tubulin
-Tubulin
-Tubulin
Ki67 Geminin
PC3-Parental
PC3-empty vector
PC3-ERK5
PC3-Parental
PC3-empty vector
PC3-ERK5
Mcm2
AB
D C
Mcm2
Merge DAPI
ERK5 Mcm2
Merge DAPI
ERK5
PC3-empty vector  PC3-ERK5 E F
Figure 2 ERK5 overexpressing PC3 stable clone. (A) Immunoblots for
ERK5 and a-tubulin of the parental PC3 line, the PC3 line transfected with
empty vector, and the PC3-ERK5 stable clone. While the PC3 line has a
background ERK5 level, the PC3-ERK5 stable clone expresses high levels of
EGFP fused ERK5 protein. (B–D) Immunoblots of Mcm2, geminin and
Ki67 in the parental PC3 line, PC3 line transfected with empty vector, and
in the PC3-ERK5 stable clone. Levels of each protein are increased in the
PC3-ERK5 stable clone. (E–F) Confocal fluorescence microscopy was
used to investigate the expression profile and cellular localisation of Mcm2
in PC3 cells overexpressing ERK5 and those expressing the Empty Vector
alone; cells were serum-starved, then stimulated with EGF. Mcm2 protein
was detected in all cells with a predominantly nuclear localisation. Mcm2
expression was higher in PC3-ERK5 cells compared to PC3-Empty Vector
cells. ERK5 expression was stronger in PC3-ERK5 cells compared to PC3-
Empty Vector cells. DAPI was used to counterstain the nucleus.
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sinitiation machinery is an early event in tumourigenesis and that
the Mcm2-7 RLFs are powerful diagnostic and prognostic markers
in a wide range of tumour types (Williams et al, 1998, 2004;
Stoeber et al, 1999; Wharton et al, 2001, 2004; Davies et al, 2002;
Going et al, 2002; Stoeber et al, 2002; Gonzalez et al, 2003; Kruger
et al, 2003; Padmanabhan et al, 2004; Dudderidge et al, 2005;
Korkolopoulou et al, 2005; Shetty et al, 2005). Recent reports have
shown that the MEK5/ERK5 pathway is implicated in the
regulation of cell proliferation, and that increased MEK5/ERK5
signalling results in increased cell proliferation, invasion and
metastatic spread during prostate carcinogenesis (Kato et al, 1998;
Mehta et al, 2003). In biochemical terms the MEK5/ERK5 pathway
is uniquely specific in that MEK5 appears to function entirely
through activation of ERK5, suggesting that this pathway could be
an attractive target for anticancer therapy in PCa. Here we have
investigated the effects of MEK5/ERK5 signalling on the DNA
replication initiation machinery in prostate carcinogenesis to
determine how this might influence origin licensing and cell cycle
kinetics of this tumour type in vivo.
Repression of origin licensing is a powerful downstream
mechanism by which human cells lower their proliferative capacity
(Stoeber et al, 2001; Blow and Hodgson, 2002; Eward et al, 2004).
Withdrawal of cells into reversible arrest (G0) or terminally
differentiated states is coupled to tight downregulation of Mcm2–7
and the origin licensing inhibitor geminin (Stoeber et al, 2001;
Eward et al, 2004; Kingsbury et al, 2005). However, MCM labelling
identifies in addition to cycling cells, non-cycling cells with
proliferative potential also. These MCM but not Ki67-expressing
cells can be found, for example, in resting tissues such as pre-
menopausal breast or primary oocytes, which retain proliferative
capacity and can rapidly respond to growth stimuli (Stoeber et al,
2001; Eward et al, 2004). Their failure to initiate DNA synthesis
and progress into S-G2-M phase is further reflected by lack of
geminin expression (Shetty et al, 2005). Expression profiling of
normal prostate shows only occasional basal Ki67, Mcm2, and
geminin-positive cells, in keeping with repression of origin
licensing during engagement of the differentiation programme in
human tissues (Stoeber et al, 2001; Eward et al, 2004). In contrast,
PCa shows high expression of RLFs and Ki67. The largest growth
fraction is identified by Mcm2, reflecting identification of both
cycling and non-cycling cells with proliferative potential. The
lower growth fraction identified by geminin compared with Ki67 is
in keeping with its expression being restricted to S-G2-M phase
(Eward et al, 2004; Wharton et al, 2004; Dudderidge et al, 2005;
Shetty et al, 2005). In vitro, increased MEK5/ERK5 signalling leads
to increased Mcm2, geminin, and Ki67 protein levels. In PCa,
increased MEK5/ERK5 signalling is coupled with an increase in the
growth fraction identified by Ki67 and Mcm2 expression and in the
Table 1 Relationship between Mcm2 LI, geminin LI, Ki67 LI, Mcm2 LI -Ki67 LI, Ki67 LI -geminin LI and geminin LI /Ki67 LI with other factors
a
n Mcm2 Geminin Ki67 Mcm2-Ki67 Ki67-geminin Geminin/Ki67
Gleason grade 6 9 17 (10–68) 1.5 (0.9–9.6) 13 (9.7–23) 6.7 (0–36) 11 (6.3–17) 13 (8.5–31)
7 7 24 (13–36) 1.7 (1.4–2.9) 15 (4.8–24) 7.7 (5.3–11) 12 (4.1–21) 13 (11–20)
8 25 32 (27–55) 4.3 (2.2–9.5) 17 (9.3–28) 19 (10–35) 12 (5.5–17) 28 (16–41)
9 12 51 (39–85) 4.6 (1.6–9.6) 30 (19–38) 30 (5.6–45) 23 (15–32) 19 (11–26)
10 5 78 (49–89) 15 (5.5–30) 49 (26–72) 16 (4.2–42) 34 (21–43) 32 (20–40)
P-value
b 0.0002 0.0003 0.004 0.06 0.001 0.21
Stage 1 13 32 (16–60) 2.7 (0.9–8.7) 23 (9.8–26) 9.9 (3.5–48) 17 (5.4–22) 12 (8.7–30)
2 15 43 (25–92) 2.9 (1.9–11) 15 (12–28) 30 (18–62) 12 (9.1–17) 20 (15–39)
3 17 38 (24–75) 3.7 (1.9–11) 17 (9.8–34) 16 (7.8–32) 13 (5.5–23) 25 (15–36)
4 5 48 (32–69) 10 (5.1–13) 37 (20–46) 16 (6.4–27) 27 (11–36) 23 (20–38)
P-value
b 0.49 0.23 0.07 0.77 0.29 0.08
Bone metastases Absent 28 46 (29–76) 3.7 (2.1–11) 22 (13–34) 19 (8.9–45) 16 (11–27) 23 (12–35)
Present 28 29 (14–63) 2.5 (1.2–8.9) 15 (8.9–24) 10 (3.5–29) 12 (5.6–19) 17 (12–32)
P-value
c 0.02 0.11 0.17 0.12 0.12 0.53
ERK5 Weak 4 12 (3.9–58) 1.2 (0.6–8.1) 9.7 (6.5–39) 2.9 (0–20) 8.5 (5.9–30) 12 (9.1–20)
Moderate 18 27 (14–43) 2.2 (1.3–5.5) 17 (12–25) 9.0 (3.1–26) 13 (9.5–20) 14 (8.7–26)
Strong 36 47 (30–71) 5.3 (2.4–11) 23 (12–35) 21 (11–35) 16 (9.0–26) 28 (17–37)
P-value
b 0.003 0.07 0.009 0.01 0.27 0.005
MEK5 Weak 6 22 (17–96) 1.8 (1.2–9.5) 12 (7.1–20) 8.9 (5.7–76) 8.4 (3.7–16) 19 (10–49)
Moderate 25 38 (23–58) 2.7 (1.1–6.5) 20 (12–32) 17 (2.5–31) 16 (10–26) 16 (8.6–23)
Strong 26 44 (26–73) 7.5 (2.2–11) 21 (13–33) 18 (7.7–36) 15 (8.5–24) 30 (16–35)
P-value
b 0.38 0.17 0.03 0.5 0.41 0.02
Overall 58 37 (21–66) 3.4 (1.5–9.3) 18 (11–31) 17 (6.3–33) 15 (8.5–22) 19 (12–34)
Note: Use significance level of 0.01 to account for multiple testing. Abbreviations: ERK5¼extracellular signal-regulated kinase-5; gemininLI/Ki67LI¼measure of the relative length
of G1 phase; Ki67LI-gemininLI¼proportion of tumour cells in G1 phase; LI¼labelling index; Mcm2LI-Ki67LI¼replication licensed but non-cycling population of tumour cells;
MEK5¼mitogen/extracellular-signal-regulated kinase kinase 5.
aValues shown are median (inter-quartile range), expressed as percentages.
bJonckheere–Terpstra test.
cMann–
Whitney U-test.
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Figure 3 Relationships between marker expression in PCa. The median
(solid black line), interquartile range (boxed), and range (enclosed by lines)
of Mcm2, Ki67 and geminin expression are shown (outlying cases are
shown by isolated points). The broader distribution of Mcm2 compared
with Ki67 reflects the additional replication licensed but non-proliferating
growth fraction, identified by Mcm2 but not Ki67. The low growth fraction
identified by geminin compared with Ki67 is in keeping with its expression
being restricted to S-G2-M phase. Overall, Mcm2 is expressed at
significantly greater levels compared with Ki67, which itself is expressed
more greatly than geminin (Wilcoxon signed-rank test, Po0.0001 in each
case).
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(Mcm2LI-Ki67LI). Interestingly, increased MEK5/ERK5 signalling
is also linked to an increase in the gemininLI to Ki67LI ratio.
Assuming that the tumour cells are not significantly delayed in
their progression through S-G2-M phase by DNA damage
checkpoints, an increase in the gemininLI to Ki67LI ratio is
indicative of a relative shortening in the length of G1 phase, the
ratio tending towards unity (B1) as G1 phase reduces in length
(Wharton et al, 2004; Eward et al, 2004; Obermann et al, 2005;
Shetty et al, 2005). Thus increased MEK5/ERK5 signalling appears
to be coupled to accelerated cell cycle progression in PCa.
Moreover, the observed changes in cell cycle parameters are
indicative of increased proliferative capacity in response to MEK5/
ERK5 signalling.
Previous studies exploiting in vitro and in vivo model systems
have shown that engagement of the somatic differentiation
programme in human cells is coupled to downregulation of the
Mcm2–7 and geminin RLFs, as cells exit the proliferative cycle and
enter the terminally differentiated state (Williams et al, 1998;
Stoeber et al, 2001; Eward et al, 2004). In this study the block to the
Mcm2 Ki67 Geminin
Gleason 10
Gleason 8
Gleason 6
Figure 4 Photomicrographs of paraffin-embedded tissue sections of different PCa Gleason grades immunohistochemically stained with antibodies to
Mcm2, Ki67 and geminin protein (positive cells stain brown). Protein expression is increased in higher grade tumours for each biomarker. Original
magnification,  400.
0
678 1 0 9
Gleason grade
20
40
60
80
100
M
c
m
2
 
l
a
b
e
l
l
i
n
g
 
i
n
d
e
x
 
(
L
I
)
Figure 5 The median (solid black line) and range of Mcm2 expression
are shown according to Gleason grade. Although there is an increase in
median Mcm2 expression with increasing grade (P¼0.0002, see also
Table 1), a high Mcm2LI does not preclude the possibility of low Gleason
grade.
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Figure 6 The median (solid black line), interquartile range (boxed), and
range (enclosed by lines) of the gemininLI to Ki67LI ratio are shown
according to ERK5 protein expression. There is a significant trend of
increasing ERK5 expression with increasing geminin/Ki67 ratio (P¼0.005;
see also Table 1), indicative of a relative shortening in the length of G1
phase and thus accelerated cell cycle progression.
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sdifferentiation programme in PCa, indicated by increasing Gleason
grade, is associated with increased expression of Ki67, Mcm2 and
geminin proteins. We also observed an increase in the number of
cells entering G1 phase with increasing Gleason grade, indicated
by an increase in Ki67LI-gemininLI. Importantly while a clear
relationship between Mcm2 protein expression and Gleason grade
has been shown in this study, high Mcm2 expression does not
preclude the possibility of low Gleason grade, indicating a broad
spectrum of growth potential within each tumour grade. Interest-
ingly, there is no association with T stage or bony metastases and
Mcm2, geminin or Ki67 protein expression. Increased expression
of MCM RLFs in response to arrested differentiation (maturation
arrest) has also been observed in other tumour types (Williams
et al, 1998; Going et al, 2002; Stoeber et al, 2002) and is currently
being assessed as a cancer screening tool in multi-centre trials
(National Cancer Research Network Trial ID 1279). This finding is
in keeping with our previous analysis of radical prostatectomy
specimens, in which we showed that Mcm2 expression, although
showing an association with primary grade and Gleason score, did
not show statistical association with T stage or metastasis (Meng
et al, 2001). This may be a reflection of the fact that PCa metastasis
is not as dependant on abrogation of cell proliferation control as
compared with other factors such as loss of cell–cell/cell–
extracellular matrix adhesion, increased cell motility, basement
membrane penetration, angioneogenesis, and immune escape
through impaired expression of surface tumour antigens (Hrouda
and Kirby, 1998).
Although increased Mcm2, geminin and Ki67 protein expression
and the replication licensed but non-cycling cell population
(Mcm2LI-Ki67LI) were all associated with significantly reduced
survival time, only Mcm2 was identified as an independent
predictor of survival on multivariate analysis. We have previously
observed that the Mcm2LI provides information with respect to
disease-free survival in PCa patients undergoing radical prosta-
tectomy (Meng et al, 2001), and our findings are also in keeping
with the recent report that Mcm7 amplification and overexpression
is associated with worse tumour grade and relapse (Ren et al,
2006).
In summary, analysis of the origin licensing pathway in PCa has
shown that dysregulation of the DNA replication licensing
machinery is a major event during prostate carcinogenesis.
The broad distribution of Mcm2 protein expression within
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Figure 7 (A–C) Association between all-cause mortality and marker expression was assessed using Kaplan–Meier curves and the log-rank test, using the
‘minimum P-value approach’ with adjusted P-values and a significance level of 0.05. A statistically significant association was found between lower Mcm2
expression and increased survival time, and between lower Ki67 expression and increased survival time. After adjustment of the P-value, the trend between
lower geminin expression and increased survival time was not statistically significant (details for each marker below). The number of patients at risk at each
time-point for each group is shown below each graph. (A) Mcm2: groups defined by o44% (n¼32), 444% (n¼26), adjusted P-value¼0.03. (B) Geminin:
groups defined by o9% (n¼43), 49% (n¼15), adjusted P-value¼0.22. (C) Ki67: groups defined by o25% (n¼38), 425% (n¼20), adjusted
P-value¼0.002. (D) Relationship between Mcm2LI and survival time.
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sGleason grades and the fact that this biomarker is an independent
predictor of survival indicate that MCM RLFs are important as
potential stratification tools for identification of PCa with
aggressive phenotypes. Moreover, our data show that induction
of MEK5/ERK5 signalling is linked to activation of the
DNA replication licensing pathway in PCa, which is associated
with marked changes in cell cycle kinetics of these tumours
indicative of a shift to increased growth potential. The strong
prognostic value of MCM RLFs appears to arise as a result of their
function as relay stations coupling upstream growth regulatory
pathways to genome duplication. Recently, the DNA replication
licensing pathway has been proposed as a selective target for anti-
cancer therapy, since tumour cells appear to be deficient in a
putative licensing checkpoint. Thus anti-cancer therapy directed at
both MEK5/ERK5 signalling and the DNA replication licensing
machinery offers an attractive approach for multitargeted therapy
in PCa.
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